We found that B2M was overexpressed in ovarian borderline and malignant tumours compared with benign tumours and normal controls, but was not associated with age, tumour size, lymph node metastasis and clinical stage. The gene discussed is B2M; the disease is metastatic malignant neoplasm in the lymph nodes.